STAT3 and neoplasm: ExoPD‐L1 can enhance the resistance of esophageal cancer cells to paclitaxel by promoting the transcription of miRNA21 by inducing STAT3 into the nucleus.[50] Notably, exoPD‐L1, rather than other extracellular forms, might serve as a biomarker for predicting tumor progression and immune checkpoint inhibitor response.